troglitazone has been researched along with Obesity, Morbid in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, LB | 1 |
| Fawcett, RL | 1 |
| Waechter, AS | 1 |
| Zhang, P | 1 |
| Kogon, BE | 1 |
| Jones, R | 1 |
| Inman, M | 1 |
| Huse, J | 1 |
| Considine, RV | 1 |
1 other study available for troglitazone and Obesity, Morbid
| Article | Year |
|---|---|
Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender.
Topics: Adipocytes; Cells, Cultured; Chromans; Dexamethasone; Female; Gene Expression Regulation; Humans; Le | 2000 |